Wedge Capital Management L L P NC Grows Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Wedge Capital Management L L P NC raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 26.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,286 shares of the specialty pharmaceutical company's stock after buying an additional 13,955 shares during the quarter. Wedge Capital Management L L P NC owned about 0.12% of Supernus Pharmaceuticals worth $2,204,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after buying an additional 1,083 shares during the last quarter. Barclays PLC lifted its position in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after buying an additional 51,005 shares during the last quarter. Two Sigma Advisers LP lifted its position in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after buying an additional 1,000 shares during the last quarter. Empowered Funds LLC acquired a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $1,498,000. Finally, Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN traded down $0.74 during mid-day trading on Friday, hitting $32.03. 590,662 shares of the company's stock were exchanged, compared to its average volume of 480,475. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.71. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The stock's 50-day moving average is $32.02 and its 200-day moving average is $34.36.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.